FILIP JANKU to Quinazolines
This is a "connection" page, showing publications FILIP JANKU has written about Quinazolines.
Connection Strength
0.531
-
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res. 2012 Nov 15; 18(22):6356-63.
Score: 0.305
-
Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018 05; 15(5):273-291.
Score: 0.111
-
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open. 2021 04; 6(2):100079.
Score: 0.034
-
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86.
Score: 0.022
-
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84.
Score: 0.020
-
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20.
Score: 0.020
-
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42.
Score: 0.019